

Figure 1 Participant flow. "Other reasons" includes inability to travel to research centre or not available at every study visit.

Characteristic	**Patients included**
Age: years	
Mean (S.D.)	38.8 (9.3)
Range	27-53
Gender: no (%)	
Men	3 (50%)
Women	3 (50%)
Body surface area (m^2)	2.10
RRMS disease duration: years	
Mean (S.D.)	9.8 (7.8)
Range	1-24
RRMS severity (EDSS)	
Mean	2.0
Range	0 - 3.5
Interval since last alemtuzumab treatment: (n)	6-9 months n=1 9-12 months n= 3 12+ months n= 2

Table 1 Participant characteristics

Type of AE	Category	Participants
Total number	Serious AE	0
	Non-serious AEs	12
Severity	AEs by severity	
	Mild	11/12 (91.7%)
	Moderate	1/12 (8.3%)
Relatedness	Related	8/12 (66.7%)
	Unrelated/unlikely	4/12 (33.3%)
Related AEs by severity	Mild	7/8 (87.5%)
	Moderate	1/8 (12.5%)
All related AEs	Injection site reaction	4 (grade I)
	Fatigue	1 (grade I)
	Headache	1 (grade I)
	Exacerbation of MS symptoms due to heat	1 (grade I)
	Worsening of existing Graves disease	1 (grade I)

Table 2 Safety and adverse events